FRANK KARBE
CIK 1276700 · Chief Financial Officer · last filed 2026-05-21
FRANK KARBE is a Chief Financial Officer who has filed 66 SEC Form 4 insider transactions across 7 companies since 2007. The most recent filing, for PHAT, was dated May 21, 2026. Across all open-market trades the lifetime net is −$911.4K, making them a net seller over the disclosed history. Current disclosed insider exposure totals $6.2M across reported positions.
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
$6.23M
7
66
-$911.4K
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| PHAT | Director | 91,622 | $10.37 | $950.1K | $99.1K | 8 | 2026-05-21 |
| Cidara Therapeutics, Inc. (CDTX) Delisted | Chief Financial Officer | 43,125 | $221.38 | $9.55M | $0 | 3 | 2026-01-07 |
| Better Therapeutics, Inc. (BTTX) Delisted | Chief Executive Officer | 526,516 | $0.04 | $23.5K | $404.7K | 5 | 2023-12-20 |
| Myovant Sciences Ltd. (MYOV) Delisted | Principal Fin'l & Accounting | 212,296 | $26.98 | $5.73M | -$1.52M | 21 | 2021-07-09 |
| CHINOOK THERAPEUTICS, INC. (ADRO) Delisted | Director | — | — | — | $0 | 3 | 2020-05-28 |
| ABUS | Director | — | $4.26 | — | $0 | 3 | 2017-06-23 |
| EXEL | EVP and CFO | 99,430 | $53.13 | $5.28M | $106.5K | 23 | 2014-02-18 |
Recent Filings
66 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2026-05-21 | PHAT | Grant (A) | +24,122 | $0 | EDGAR |
| 2026-01-07 | Cidara Therapeutics, Inc. (CDTX) Delisted | Disp (D) | −50,651 | -$1.67M | EDGAR |
| 2025-12-12 | Cidara Therapeutics, Inc. (CDTX) Delisted | Tax (F) | −7,290 | -$1.60M | EDGAR |
| 2025-06-05 | PHAT | Grant (A) | +10,500 | $0 | EDGAR |
| 2025-02-26 | Cidara Therapeutics, Inc. (CDTX) Delisted | Grant (A) | +57,500 | $0 | EDGAR |
| 2024-12-16 | PHAT | Buy (P) | +12,500 | $99.1K | EDGAR |
| 2024-05-31 | PHAT | Grant (A) | +25,000 | $254.1K | EDGAR |
| 2024-05-24 | PHAT | Grant (A) | +10,500 | $0 | EDGAR |
| 2023-12-20 | Better Therapeutics, Inc. (BTTX) Delisted | Grant (A) | +62,500 | $0 | EDGAR |
| 2023-07-31 | Better Therapeutics, Inc. (BTTX) Delisted | Buy (P) | +137,005 | $100.0K | EDGAR |